Document:

EX-10.36

 Exhibit 10.36 

 

			
	

	  	9721 Sherrill Blvd. | Knoxville, TN 37932
		  	865-560-4695 | fax 865-560-4710
		  	ken.lowe@scrippsnetworks.com
	Kenneth W. Lowe	  	
	Chairman of the Board, President, Chief Executive Officer	  	Assistant: Nancy Walters | 865-560-4641 | nwalters@scrippsnetworks.com

 April 29, 2013 
 Dennis Shuler 
 8120 Shawnee Run Road 
 Cincinnati Ohio 45243 
  

	Re:	Employment Agreement 

 Dear Dennis:

 Scripps Networks Interactive, Inc. (the “Company”), either directly or through one of its subsidiaries, agrees to employ you and
you agree to accept such employment upon the following terms and conditions: 
 l. Term. Subject to the provisions for earlier
termination provided in paragraph 8 below, the term of your employment hereunder shall become effective as of April 29, 2013 and continue until April 30, 2016. Such period shall be referred to as the “Term,” notwithstanding any
earlier termination of your employment for any reason. The Company shall provide you with at least ninety (90) days’ notice prior to the expiration of the Term if the Company does not intend to continue to employ you beyond the expiration
of the Term. If the Company does not provide you with such notice and the Company and you do not agree in writing to renew or extend this Agreement or enter into a new employment agreement upon the expiration of the Term, the parties agree that,
notwithstanding the expiration of this Agreement, you shall continue to be employed by the Company on an at-will basis which means that either you or the Company may terminate the employment relationship at any time upon thirty (30) days’
prior written notices, with or without cause, and your Annual Salary will continue on a pro-rated basis. 
 2. Duties. You will be the
Executive Vice President, Chief Human Resources Officer, reporting to the Chairman, President and Chief Executive Officer (“Reporting Senior”). You agree as a member of management to devote substantially all your business time, and apply
your best reasonable efforts, to promote the business and affairs of the Company and its affiliated companies during your employment. You will perform such duties and responsibilities commensurate with your position and title during the Term, and as
may be reasonably assigned to you from time to time by your Reporting Senior. You shall not, without the prior written consent of the Company, directly or indirectly, during the Term, other than in the performance of duties naturally inherent to the
businesses of the Company and in furtherance thereof, render services of a business, professional, or commercial nature to any other person or firm, whether for compensation or otherwise; provided, however, that so long as it does not

 Dennis Shuler 
 March 1, 2013 
  Page
 2
 
  

 
materially interfere with the performance of your duties hereunder, you may serve as a director, trustee or officer of, or otherwise participate in, educational, welfare, social, religious,
civic, professional, or trade organizations. Your principal place of employment shall be in Knoxville, Tennessee. 
 3. Compensation.

 (a) Annual Salary. For all the services rendered by you in any capacity under this Agreement, the Company agrees to pay you no less
than $550,000 a year in base salary (“Annual Salary”), less applicable deductions and withholding taxes, in accordance with the Company’s payroll practices as they may exist from time to time during the Term. Your Annual Salary may be
increased by the Company in conjunction with your annual performance review conducted pursuant to the guidelines and procedures of the Company applicable to similarly situated executives, but in no event shall your Annual Salary be less than the
annual salary amount established under this paragraph 3(a) for the immediately previous calendar year. 
 (b) Annual Incentive. During
your employment hereunder, you shall be eligible to participate in the Company’s applicable Annual Incentive Plan, as amended, or any successor to such plan (the “Annual Incentive Plan”) with a target annual incentive opportunity of
50% of your Annual Salary as established under paragraph 3(a) (“Annual Incentive”). The Annual Incentive amount actually paid shall be based on your attainment of, within the range of the minimum and maximum performance objectives,
strategic and financial goals established for you by the Company. The Company shall pay to you any Annual Incentive under this paragraph 3(b) in accordance with the terms and subject to the conditions of the Annual Incentive Plan. 

(c) Equity Award. On May 14, 2013 (the “Grant Date”), the Company shall grant to you a restricted share unit award (the
“Restricted Share Unit”) that covers a number of units (rounded to the nearest whole unit) obtained by dividing (i) $400,000, by (ii) the closing per-share price of the Company’s Class A Common Shares as listed on the
New York Stock Exchange on the Grant Date. The Restricted Share Unit shall be granted upon the terms, and subject to the conditions, of the 2008 Long-Term Incentive Plan and the award agreement evidencing the grant of the Restricted Share Unit, a
copy of which is attached as Exhibit A to this Agreement. 
 4. Benefits. During your employment hereunder, you shall be eligible
to participate in all equity incentive plans of the Company applicable to similarly situated executives of the Company in accordance with the terms of each plan. During your employment hereunder, you shall also be entitled to participate in any
employee retirement, pension and welfare benefit plan or program available to similarly situated executives of the Company, or to the Company’s employees generally, as such plans and programs may be in effect from time to time, including,

 Dennis Shuler 
 March 1, 2013 
  Page
 3
 
  

 
without limitation, pension, profit sharing, savings, estate preservation and other retirement plans or programs, 401(k), medical, dental, life insurance, short-term and long-term disability
insurance plans, accidental death and dismemberment protection, travel accident protection, and all other plans that the Company may have or establish from time to time and in which you would be entitled to participate under the terms of the
applicable plan for similarly situated executives. This provision is not intended, nor shall it have the effect of, reducing any benefit to which you were entitled as of the effective date of this Agreement. However, this provision shall not be
construed to require the Company to establish any welfare, compensation or long-term incentive plans, or to prevent the modification or termination of any plan once established, and no action or inaction with respect to any plan shall affect this
Agreement. You shall be entitled to be reimbursed by the Company for tax and financial planning up to a maximum net amount of $10,000 per year. In addition, the Company shall pay the cost of an annual “senior executive” physical
examination. 
 5. Business Expenses. During your employment hereunder, upon delivery of proper documentation in accordance with the
Company’s expense reimbursement policy, the Company shall reimburse you for reasonable travel and other expenses incurred in the performance of your duties as are customarily reimbursed to similarly situated executives of the Company.

 6. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit your continuing or future participation in any plan,
program, policy or practice provided by the Company or its affiliates and for which you may qualify that are provided to any other similarly situated executives. Amounts that are vested benefits or that you are otherwise entitled to receive under
any plan, policy, practice or program of or any contract or agreement with the Company or its affiliates at or subsequent to the date of termination shall be payable in accordance with such plan, policy, practice or program or contract or agreement
except as explicitly modified by this Agreement. 
 7. Non-Competition, Confidential Information, Etc. 

(a) Non-Competition. You agree that your employment with the Company is on an exclusive basis and that, while you are employed by the Company, you
will not engage in any other business activity that would otherwise conflict with your duties and obligations (including your commitment of substantially all business time) under this Agreement. You agree that, during the Non-Compete Period (as
defined below), you shall not directly or indirectly engage in or participate as an owner, partner, stockholder, officer, employee, director, agent of or consultant for any business competitive with any business of the Company, or for any customer
of the Company, without the prior written consent of the Company; provided, however, that this provision shall not prevent you from investing as a less-than-one-percent (1%) stockholder in the securities of any company listed on a
national securities exchange or quoted on an automated quotation system. The Non-Compete Period 

 Dennis Shuler 
 March 1, 2013 
  Page
 4
 
  

 
shall cover the entire Term, unless earlier terminated as set forth in Sections 8(b) or (c) as well as twelve (12) months after your employment with the Company terminates for any
reason, or on such earlier date as you may make the election under paragraph 7(i) (which relates to your ability to terminate your obligations under this paragraph 7(a) in exchange for waiving your right to certain compensation and benefits).

 (b) Confidential Information. You agree that, during the Term or at any time thereafter: (i) you shall not use for any purpose
other than the duly authorized business of the Company, or disclose to any third party, any information relating to the Company or any of its affiliated companies which is proprietary to the Company or any of its affiliated companies
(“Confidential Information”), including any trade secret or any written (including in any electronic form) or oral communication incorporating Confidential Information in any way (except as may be required by law or in the performance of
your duties under this Agreement consistent with the Company’s policies); and (ii) you will comply with any and all confidentiality obligations of the Company to a third party, whether arising under a written agreement or otherwise.
Information shall not be deemed Confidential Information which: (x) is or becomes generally available to the public other than as a result of a disclosure by you or at your direction or by any other person who directly or indirectly
receives such information from you, or (y) is or becomes available to you on a non-confidential basis from a source which is entitled to disclose it to you. 
 (c) No Solicitation or Interference. You agree that, during the Term and for one (1) year thereafter, no matter how the Term ends, you shall not, directly or indirectly: (i) employ or
solicit the employment of any person who is then or has been within six (6) months prior thereto, an employee, independent contractor or consultant of the Company or any of its affiliated companies; or (ii) interfere with, disturb or
interrupt the relationships (whether or not such relationships have been reduced to formal contracts) of the Company or any of its affiliated companies with any talent, production companies, vendors, advertisers (including, without limitation their
agencies or representatives), sponsors, distributors, customers, suppliers, agents, consultants or independent contractors. 
 (d) Ownership
of Works. The results and proceeds of your services under this Agreement, including, without limitation, any works of authorship resulting from your services to the Company or any of its affiliates during your employment with the Company and/or
any of its affiliated companies and any works in progress resulting from such services, shall be works-made-for-hire and the Company shall be deemed the sole owner throughout the universe of any and all rights of every nature in such works, whether
such rights are now known or hereafter defined or discovered, with the right to use the works in perpetuity in any manner the Company determines in its sole discretion without any further payment to you. If, for any reason, any of such results and
proceeds are not legally deemed a work-made-for-hire and/or there are any rights in such results and proceeds which do not accrue to the Company under the preceding sentence, then you hereby irrevocably assign and agree to assign any and all of your
right, title and interest thereto, 

 Dennis Shuler 
 March 1, 2013 
  Page
 5
 
  

 
including, without limitation, any and all copyrights, patents, trade secrets, trademarks and/or other rights of every nature in the work, whether now known or hereafter defined or discovered,
and the Company shall have the right to use the work in perpetuity throughout the universe in any manner the Company determines in its sole discretion without any further payment to you. You shall, as may be requested by the Company from time to
time, do any and all things which the Company may deem useful or desirable to establish or document the Company’s rights in any such results and proceeds, including, without limitation, the execution of appropriate copyright, trademark and/or
patent applications, assignments or similar documents and, if you are unavailable or unwilling to execute such documents, you hereby irrevocably designate your Reporting Senior or his designee as your attorney-in-fact with the power to execute such
documents on your behalf. To the extent you have any rights in the results and proceeds of your services under this Agreement that cannot be assigned as described above, you unconditionally and irrevocably waive the enforcement of such rights. This
paragraph 7(d) is subject to, and does not limit, restrict, or constitute a waiver by the Company or any of its affiliated companies of any ownership rights to which the Company or any of its affiliated companies may be entitled by operation of law
by virtue of being your employer. 
 (e) Litigation. 
  

	 	(i)	You agree that, during the Term, for one (1) year thereafter and, if longer, during the pendency of any litigation or other proceeding, and except as may be
required by law or legal process: (x) you shall not communicate with anyone (other than your own attorneys and tax advisors), except to the extent necessary in the performance of your duties under this Agreement, with respect to the
facts or subject matter of any pending or potential litigation of which you have knowledge, or regulatory or administrative proceeding involving the Company or any of its affiliated companies, other than any litigation or other proceeding in which
you are a party-in-opposition, without giving prior notice to the Company’s Chief Legal Officer; and (y) in the event that any other party attempts to obtain information or documents from you with respect to such matter, either
through formal legal process such as a subpoena or by informal means such as interviews, if you are legally permitted to do so, you shall promptly notify the Company’s Chief Legal Officer before providing any information or documents.

  

	 	(ii)	 You agree to cooperate with the Company and its attorneys, both during employment and during the five (5) year period following termination of
your employment, in connection with any litigation or other proceeding arising out of or relating to matters in which you were involved prior to the termination of your employment. Your cooperation shall include, without limitation, providing
assistance to the Company’s counsel, experts or consultants, and providing truthful testimony in pretrial and 

 Dennis Shuler 
 March 1, 2013 
  Page
 6
 
  

	 	
trial or hearing proceedings. In the event that your cooperation is requested after the termination of your employment, the Company will: (x) seek to minimize interruptions to your
schedule to the extent consistent with its interests in the matter; and (y) reimburse you for all reasonable and appropriate out-of-pocket expenses actually incurred by you in connection with such cooperation upon reasonable
substantiation of such expenses. 

  

	 	(iii)	Except as required by law or legal process, or as requested by the Company’s Chief Legal Officer, you agree that you will not testify in any lawsuit or other
proceeding which directly or indirectly involves the Company or any of its affiliated companies that was not filed by you, or which may create the impression that such testimony is endorsed or approved by the Company or any of its affiliated
companies. In all events, if legally permitted to do so, you shall give advance notice to the Company’s Chief Legal Officer that you will be testifying promptly after you become aware that you may be required to provide it. The Company
expressly reserves its attorney-client and other privileges except if expressly waived in writing. 

 (f) Return of
Property. All documents, data, recordings, or other property, whether tangible or intangible, including all information stored in electronic form, obtained or prepared by or for you and utilized by you in the course of your employment with the
Company or any of its affiliated companies shall remain the exclusive property of the Company. In the event of the termination of your employment for any reason, the Company reserves the right, to the extent permitted by law and in addition to any
other remedy either may have, to deduct from any monies otherwise payable to you the following: (i) all amounts you may directly owe to the Company or any of its affiliated companies at the time of or subsequent to the termination of your
employment with the Company; and (ii) the reasonable value of the Company property which you retain in your possession after the termination of your employment with the Company. In the event that the law of any state or other jurisdiction
requires the consent of an employee for such deductions, this Agreement shall serve as such consent. 
 (g) Non-Disparagement. During the
duration of your employment and for one (1) year following the termination thereof for any reason, you shall not make, nor cause any one else to make or cause on your behalf, any public disparaging or derogatory statements or comments regarding
the Company or its affiliated companies, or its officers or directors; likewise, the Company’s officers will not make, nor cause any one else to make, any public disparaging or derogatory statements or comments regarding you. 

(h) Injunctive Relief. The Company has entered into this Agreement in order to obtain the benefit of your unique skills, talent, and experience.
You and the Company acknowledge and agree that your violation of one or all of paragraphs 

 Dennis Shuler 
 March 1, 2013 
  Page
 7
 
  

 
7(a) through (h) of this Agreement will result in irreparable damage to the Company and/or its affiliated companies and, accordingly, the Company may obtain injunctive and other equitable
relief for any breach or threatened breach of such paragraphs, in addition to any other remedies available to the Company. 
 (i) Survival;
Modification of Terms. The obligations set forth under paragraphs 7(a) through (i) shall remain in full force and effect for the entire period provided therein notwithstanding the termination of your employment under this Agreement for any
reason or the expiration of the Term; provided, however, that your obligations under paragraph 7(a) (but not under any other provision of this Agreement) shall cease if you terminate your employment for Good Reason or the Company
terminates your employment without Cause and you notify the Company in writing, prior to the Company’s payment of any severance benefits pursuant to paragraphs 8(e)(iii) through (vii) and payable pursuant to terms of the
Company’s Executive Severance Plan, you waive your right to receive termination payments and benefits in accordance with paragraph 8(e)(iii) through (vii) payable pursuant to the terms of the Company’s Executive Severance Plan.
You and the Company agree that the restrictions and remedies contained in paragraphs 7(a) through (h) are reasonable and that it is your intention and the intention of the Company that such restrictions and remedies shall be enforceable to the
fullest extent permissible by law. If a court of competent jurisdiction shall find that any such restriction or remedy is unenforceable but would be enforceable if some part were deleted or the period or area of application reduced, then such
restriction or remedy shall apply with the modification necessary to make it enforceable. For avoidance of doubt, you will not be required to waive your rights to receive the payment under paragraphs 8(e)(i) and (ii) if you wish to be released
from paragraph 7(a). 
 8. Termination. 
 (a) Termination for Cause. The Company may, at its option, terminate your employment under this Agreement for Cause and thereafter shall have no obligations under this Agreement, including, without
limitation, any obligation to pay Annual Salary or Annual Incentive or provide benefits, excluding any and all earned and/or vested compensation and/or benefits. “Cause” shall mean exclusively: (i) embezzlement, fraud or other conduct
that would constitute a felony (other than traffic-related citations); (ii) willful unauthorized disclosure of Confidential Information; (iii) your material breach of this Agreement; (iv) your gross misconduct or gross neglect in the
performance of your duties hereunder; (v) your willful failure to cooperate with a bona fide internal investigation or investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the
willful destruction or failure to preserve documents or other material reasonably known to be relevant to such an investigation, or the willful inducement of others to fail to cooperate or to destroy or fail to produce documents or other material;
or (vi) your willful and material violation of the Company’s written conduct policies, including but not limited to the Company’s Employment Handbook and Ethics Code. The Company will give you

 Dennis Shuler 
 March 1, 2013 
  Page
 8
 
  

 
written notice prior to terminating your employment pursuant to (iii), (iv), (v), or (vi), of this paragraph 8(a), setting forth the nature of any alleged failure, breach or refusal in reasonable
detail and the conduct required to cure. Except for a failure, breach or refusal which, by its nature, cannot reasonably be expected to be cured, you shall have twenty (20) business days from the giving of such notice within which to cure any
failure, breach or refusal under (iii), (iv), (v), or (vi) of this paragraph 8(a); provided, however, that, if the Company reasonably expects irreparable injury from a delay of twenty (20) business days, the Company may give
you notice of such shorter period within which to cure as is reasonable under the circumstances. 
 (b) Good Reason Termination. You may
terminate your employment under this Agreement for Good Reason at any time during the Term by written notice to the Company in accordance with the Company’s Executive Severance Plan. “Good Reason” shall mean without your consent
(other than in connection with the termination or suspension of your employment or duties for Cause or in connection with your Disability) exclusively: (i) a material diminution in your Annual Salary or target Annual Incentive opportunity;
(ii) a material diminution in your authority, duties, or responsibilities; (iii) a material diminution in the authority, duties, or responsibilities of the supervisor to whom you are required to report; (iv) a requirement that you
report to someone else other than your Reporting Senior or similar positions then in effect that results in a material change in your reporting structure; (v) a material diminution in the budget over which you retain authority (except for good
faith budget adjustments necessitated by the legitimate business needs of the Company); (vi) a material change in geographic location at which you must perform services under this Agreement from the Company’s offices at which you were
principally employed; or (vii) any other action or inaction that constitutes a material breach by the Company of the terms of the Agreement. Notwithstanding the foregoing, no event described above shall constitute Good Reason unless:
(1) you give notice of termination for Good Reason to the Company in accordance with the Company’s Executive Severance Plan specifying the condition or event relied upon for such termination within ninety (90) days from when you first
become aware of such event or condition; and (2) the Company fails to cure the condition or event constituting Good Reason within thirty (30) calendar days after receipt of such notice. 

(c) Termination Without Cause or for Disability. The Company may terminate your employment under this Agreement without Cause or for
“Disability” (defined by reference to the employee long-term disability plan of the Company or a subsidiary that covers you) at any time during the Term by written notice to you in accordance with the Company’s Executive Severance
Plan at least thirty (30) days prior to the date of such termination. 
 (d) Termination as a Result of Death. Your employment with
the Company shall terminate in the event of your death. 

 Dennis Shuler 
 March 1, 2013 
  Page
 9
 
  

 (e) Termination Payments/Benefits. Subject to paragraph 7 and, as applicable, paragraph 9, and
pursuant to the terms, and subject to the conditions, of the Company’s Executive Severance Plan, but in no event less than the benefits as provided in this Agreement, in the event that your employment terminates under paragraph 8(b),
(c) or (d) or upon the failure of the parties to renew this Agreement and your employment is terminated without cause as a result, you (or your estate or legal representative, if applicable) shall thereafter receive the following benefits
(in each case less applicable deductions and withholding taxes) ); provided, however, that in no event shall you receive the following benefits if your employment terminates (x) on account of your mandatory retirement in accordance with the
Company’s mandatory retirement program, if any, applicable to you, (y) on account of your voluntary termination of employment, with or without Good Reason, on or after attaining age 65, or (z) of your own initiative for any reason
other than Good Reason: 
  

	 	(i)	Accrued Benefits: The portion of your Annual Salary earned, but not yet paid, through your Date of Termination; any Annual Incentive earned, but not yet paid,
for a completed fiscal year preceding the Date of Termination; and any accrued paid vacation, sick leave, sabbatical, holiday and other paid-time off, to the extent not yet paid (collectively, the “Accrued Benefits”). The Accrued Benefits
shall be paid in a single lump sum within 30 calendar days after your Date of Termination, or as otherwise may be provided in a valid deferral election made pursuant to the terms of the Company’s deferred compensation plan.

  

	 	(ii)	Pro-Rated Annual Incentive. A Pro-Rated Annual Incentive, which shall be paid in a single lump sum at the same time that payments are made to other participants
in the annual incentive plan for that fiscal year (pursuant to the terms of the applicable plan but in no event later than March 15 of the fiscal year immediately following the fiscal year during which your Date of Termination occurs), or as
otherwise may be provided in a valid deferral election made pursuant to the terms of the Company’s deferred compensation plan, and shall be in lieu of any annual incentive that you would have otherwise been entitled to receive under the terms
of the annual incentive plan covering you for the fiscal year during which your Date of Termination occurs. 

  

	 	(iii)	Severance Payment. As additional severance (and not in lieu of any annual incentive for the fiscal year in which your Date of Termination occurs), a severance
payment equal to 1.5 times the sum of your Base Salary and Target Annual Incentive. The severance shall be paid in a single lump sum within 20 calendar days after the Release Deadline. 

 

	 	(iv)	 Health Care Coverage. As long as you (or your estate or legal representative) pays the required full monthly premiums for coverage, the Company
shall provide you and, as applicable, your eligible dependents with continued medical and dental coverage, on the same 

 Dennis Shuler 
 March 1, 2013 
  Page
 10
 
  

	 	
basis as provided to Company’s active executives and their dependents for 1.5 years or such longer period as required by law (or, if earlier, until you first become eligible for any such
coverage under a plan maintained by another employer or your spouse’s employer) (the “Benefit Continuation Period”). In addition, within 20 calendar days after the Release Deadline, the Company shall pay to you a lump sum cash payment
equal to 18 times the monthly medical and dental premiums based on the level of coverage in effect for you (e.g., employee only or family coverage) on the Date of Termination; provided, however, that to the extent necessary to avoid a
violation of Section 409A, any cash payment attributable to medical and dental insurance premiums for periods more than 18 months after your Date of Termination, shall be paid in monthly installments at the same time that such premiums are due
and payable. The Benefit Continuation Period shall run concurrently with (and shall count against) the Company’s obligation to provide continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act.

  

	 	(v)	Life Insurance. The Company shall take all steps reasonably necessary to continue the life insurance coverage applicable to you on your Date of Termination (and
if the policy cannot be continued in its then-current form, the Company shall exercise any required conversion features to continue the policy), at no cost to you, for 1.5 years following your Date of Termination. The amount of such coverage will be
reduced by the amount of life insurance coverage furnished to you at no cost by a third party employer. 

  

	 	(vi)	Financial Planning. An net amount of $10,000, which is intended to cover the approximate cost of financial planning services for you for a period of one year
after your Date of Termination. This financial planning stipend shall be paid in a single lump sum within 20 calendar days after the Release Deadline. 

  

	 	(vii)	Outplacement. The Company shall, at its sole expense as incurred, provide you with outplacement services from a recognized outplacement service provider for 12
months, the scope of such services to be determined in the sole discretion of the Company. 

 (f) Termination of Benefits.
Notwithstanding anything in this Agreement to the contrary (except as otherwise provided in paragraph 8(e) with respect to medical and dental benefits, life insurance, financial planning and outplacement), participation in all the Company
benefit plans and programs will terminate upon the termination of your employment except to the extent otherwise expressly provided in such plans or programs and subject to any vested rights you may have under the terms of such plans or programs.

 Dennis Shuler 
 March 1, 2013 
  Page
 11
 
  

 (g) Resignation from Official Positions. If your employment with the Company terminates for any
reason, you shall be deemed to have resigned at that time from any and all officer or director positions that you may have held with the Company or any of its affiliated companies and all board seats or other positions in other entities you held on
behalf of the Company. If, for any reason, this paragraph 8(g) is deemed insufficient to effectuate such resignation, you agree to execute, upon the request of the Company, any documents or instruments which the Company may deem necessary or
desirable to effectuate such resignation or resignations, and you hereby authorize the Secretary and any Assistant Secretary of the Company to execute any such documents or instruments as your attorney-in-fact. 

9. Severance Contingent On Release. Any compensation and benefits to be provided under the Company’s Executive Severance Plan and described
in paragraph 8(e)(ii), (iii), (iv), (v), (vi) or (vii) shall be provided only if you (or in the case of your death or Disability, your legal representative, if applicable) execute and do not later revoke or materially violate a release of
claims the form of that certain Form of Release attached to the Company’s Executive Severance Plan (with such changes as the Company may determine to be required or reasonably advisable in order to make the release enforceable and otherwise
compliant with applicable law) (the “Release”). The Release must be executed by you and become effective and irrevocable in accordance with its terms no later than the fifty-second (52nd) day following termination of your employment
(the “Release Deadline”). 
 10. Company’s Policies. You agree that, during your employment hereunder, you will comply in
all material respects with all of the Company’s written policies, including, but not limited to, the Company’s Employee Handbook and Code of Ethics. 
 11. Indemnification; Liability Insurance. If you are made a party to, are threatened to be made a party to, receive any legal process in, or receive any discovery request or request for information
in connection with, any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that you were an officer, director, employee, or agent of the Company or any of its
affiliated companies, or were serving at the request of or on behalf of the Company or any of its affiliated companies, the Company shall indemnify and hold you harmless to the fullest extent permitted or authorized by the Company’s Articles of
Incorporation or Code of Regulations or, if greater, by the laws of the State of Tennessee, against all costs, expenses, liabilities and losses you incur in connection therewith. Such indemnification shall continue even if you have ceased to be an
officer, director, employee or agent of the Company or any of its affiliated companies, and shall inure to the benefit of your heirs, executors and administrators. The Company shall reimburse you for all costs and expenses you incur in connection
with any Proceeding within twenty (20) business days after receipt by the Company of a written request for such reimbursement and appropriate documentation associated with such expenses. In addition, the Company agrees to maintain a
director’s and officer’s liability 

 Dennis Shuler 
 March 1, 2013 
  Page
 12
 
  

 
insurance policy or policies covering you at a level and on terms and conditions no less favorable than the Company provides it directors and senior-level officers currently (subject to any
future improvement in such terms and conditions), until such time as legal or regulatory action against you are no longer permitted by law. 

12. Notices. All notices under this Agreement must be given in writing, by personal delivery facsimile or by mail, if to you, to the address shown
on this Agreement (or any other address designated in writing by you), with a copy to any other person you designate in writing, and, if to the Company, to your Reporting Senior to the address shown on this Agreement (or any other address designated
in writing by the Company), with a copy, to the attention of the Company’s Chief Legal Officer. Any notice given by mail shall be deemed to have been given three (3) days following such mailing. 

13. Assignment. This is an Agreement for the performance of personal services by you and may not be assigned by you, without the prior written
consent of the Company, otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by your legal representatives. This Agreement shall inure to the benefit of and be binding upon
the Company and its successors and assigns. Except as provided in the immediately following sentence, this Agreement shall not be assignable by the Company without your prior written consent. The Company will require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company
would be required to perform if no such succession had taken place. “Company” means the Company as defined in this Agreement and any successor to its business and/or assets as described above that assumes and agrees to perform this
Agreement by operation of law or otherwise. 
 14. Governing Law. This Agreement shall be governed by, and construed in accordance with,
the laws of the State of Tennessee. 
 15. No Implied Contract. Nothing contained in this Agreement shall be construed to impose any
obligation on the Company or you to renew this Agreement or any portion thereof. The parties intend to be bound only upon execution of a written agreement and no negotiation, exchange of draft or partial performance shall be deemed to imply an
agreement. Neither the continuation of employment nor any other conduct shall be deemed to imply a continuing agreement upon the expiration of the Term. 
 16. Entire Understanding. Except where specifically stated otherwise herein, this Agreement contains the entire understanding of the parties hereto relating to the subject matter contained in this
Agreement, and can be changed only by a writing signed by both parties. Capitalized terms used in this Agreement without definition shall have the meaning given to such terms in the Company’s Executive Severance Plan. 

 Dennis Shuler 
 March 1, 2013 
  Page
 13
 
  

 17. Void Provisions. If any provision of this Agreement, as applied to either party or to any
circumstances, shall be found by a court of competent jurisdiction to be unenforceable but would be enforceable if some part were deleted or the period or area of application were reduced, then such provision shall apply with the modification
necessary to make it enforceable, and shall in no way affect any other provision of this Agreement or the validity or enforceability of this Agreement. 
 18. Deductions and Withholdings. All amounts payable under this Agreement shall be paid less deductions and income and payroll tax withholdings as may be required under applicable law. 

19. Section 409A of the Code. It is the Company’s intent that this Agreement be exempt from the application of, or otherwise comply
with, the requirements of Section 409A of the Internal Revenue Code. In particular, any expense eligible for reimbursement must be incurred, or any entitlement to a benefit must be used, during the Term (or the applicable expense reimbursement
or benefit continuation period provided in this Agreement). The amount of the reimbursable expense or benefit to which you are entitled during a calendar year will not affect the amount to be provided in any other calendar year, and your right to
receive the reimbursement or benefit is not subject to liquidation or exchange for another benefit. Provided the requisite documentation is submitted, the Company will reimburse the eligible expenses on or before the last day of the calendar year
following the calendar year in which the expense was incurred. 
 If the foregoing correctly sets forth our understanding,
please sign, date and return an original executed copy to me for our records. 
  

					
	Sincerely yours,	  	
	
	SCRIPPS NETWORKS INTERACTIVE, INC.
		
	Kenneth W. Lowe	  	
		
	Attachment	  	
	
	ACCEPTED AND AGREED:
		
	  
	  	
	Dennis Shuler	  	
	Dated:EX-4.6

 Exhibit 4.6 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND
PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT TO PURCHASE STOCK 

 

			
	Corporation:	    	REGADO BIOSCIENCES, INC., a Delaware corporation
	Number of Shares:	    	See Below
	Class of Stock:	    	Series E Preferred (Subject to Section 1.6)
	Warrant Price:	    	$0.72 per share (Subject to Section 1.6)
	Issue Date:	    	May 10, 2013
	Expiration Date:	    	May 10, 2023 (Subject to Section 4.1)

 THIS WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable
consideration, the receipt of which is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of the class of securities
of REGADO BIOSCIENCES, INC. (the “Company”) at the Warrant Price, all as set forth above and herein and as adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the terms and conditions set forth in this
Warrant. 
 The initial number of fully paid and non-assessable shares for which this Warrant shall be exercisable shall equal
156,250 (the “Initial Shares”). Upon issuance of the Tranche B Growth Capital Advance (as defined in the Loan and Security Agreement between Company and Holder dated as of the Issue Date (the “Loan Agreement”)) made
under the Loan Agreement as of May 10, 2014, this Warrant shall be automatically exercisable for, in addition to the Initial Shares, an additional number of fully paid and non-assessable shares equal to (i) 100,000, divided by
(ii) the Warrant Price (the “Additional Shares” and, together with the Initial Shares, the “Shares”), all as set forth above and as adjusted pursuant to Section 1.6 and Section 2 of this Warrant.

 ARTICLE 1 
 EXERCISE 
 1.1 Method of Exercise. Holder may exercise this Warrant
by a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the Company (or such other appropriate location as Holder is so instructed by the Company). Holder shall also deliver to the Company a
check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2 [Reserved]. 
 1.3 Delivery of Certificate and New Warrant. Within thirty (30) days after Holder exercises this Warrant and the Company receives payment of the aggregate Warrant Price, the Company shall
deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired. 

 1.4 Replacement of Warrants. In the case of loss, theft or destruction of this
Warrant, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu
of this Warrant, a new warrant of like tenor. 
 1.5 Acquisition of the Company. 

1.5.1 “Acquisition.” For the purpose of this Warrant, “Acquisition” means (a) any sale, license, or other
disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger, sale of the voting securities of the Company or other transaction or series of related
transactions where the holders of the Company’s securities before the transaction or series of related transactions beneficially own less than fifty percent (50%) of the outstanding voting securities of the surviving entity after the
transaction or series of related transactions. 
 1.5.2 Treatment of Warrant in the Event of an Acquisition. The Company
shall give Holder written notice at least twenty (20) days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer of the Company, (ii) successor or surviving
entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume this Warrant as a part of the Acquisition. 
 (a) If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and the Warrant Price and number and class of Shares shall continue to be
subject to adjustment from time to time in accordance with the provisions hereof. 
 (b) If the Acquirer refuses to assume this
Warrant in connection with the Acquisition, the Company shall give Holder an additional written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any other provision of this
Warrant to the contrary, Holder may immediately exercise this Warrant in the manner specified in this Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant, then this
Warrant will terminate immediately prior to the closing of the Acquisition. Notwithstanding any other provision of this Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in
connection with an Excluded Acquisition (as defined below), then effective as of the date that is ten (10) days prior to the closing of such Acquisition, the Holder shall have the option to elect (i) that the Warrant Price be adjusted,
without further action of any party, to $0.01 per share or (ii) to put this Warrant to the Company for a per Share amount equal to the difference between the Acquisition consideration payable for one Share and the Warrant Price. As used herein,
an “Excluded Acquisition” means, an Acquisition where the consideration that the holders of the Shares are entitled to receive on account of the Shares consists entirely of cash and/or shares of common stock that are publicly traded on a
national exchange and where the shares, if any, receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the closing of such Acquisition may be publicly re-sold by the Holder in their entirety
within the three (3) months following such closing pursuant to Rule 144 or an effective registration statement under the Act. 

  

- 2 - 

 1.6 Adjustment in Underlying Preferred Stock Price and Warrant Price. If any time
after the Issue Date the Company sells and issues to any investors preferred stock at a price per share that is less than the Warrant Price, this Warrant shall, at Holder’s option, concurrent with the issuance of such shares of preferred stock,
automatically be adjusted to instead be exercisable for shares of the same series and class and bearing the same rights, preferences, and privileges of such shares of stock, with the Warrant Price hereunder adjusted to equal the per share purchase
price of such stock, and the number of such shares subject to this Warrant adjusted to equal (i) 112,500 plus, if the Tranche B Growth Capital Advance has been made under the Loan Agreement, 100,000, divided by (ii) such modified per share
Warrant Price. 
 ARTICLE 2 
 ADJUSTMENTS TO THE SHARES 
 2.1 Stock Dividends, Splits, Etc. If the
Company declares or pays a dividend on its common stock payable in common stock, or other securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this Warrant, for each Share acquired,
Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred. 

2.2 Reclassification, Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results in
a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder
would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic conversion of the outstanding or issuable securities of
the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Amended and Restated Certificate of Incorporation upon the closing of a registered public offering of the Company’s common stock.
The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided
for in this Article 2 including, without limitation, adjustments to the Warrant Price, the number of securities or property issuable upon exercise of the new warrant and expiration date. The provisions of this Section 2.2 shall similarly apply
to successive reclassifications, exchanges, substitutions, or other events. 
 2.3 Adjustments for Combinations, Etc. If
the outstanding Shares are combined or consolidated, by reclassification, reverse split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are split or multiplied, by
reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be proportionately decreased. 
 2.4
Adjustments for Diluting Issuances. If the Shares are shares of Series E Preferred Stock, then, in the event of any issuance or deemed issuance by the Company of shares of Common Stock after the Issue Date of this Warrant that would result in
an adjustment to the conversion price of the Series E Preferred Stock (a “Diluting Issuance”), then the number of shares of common stock issuable upon conversion of the Shares shall (without duplication of any adjustment in accordance with
the Certificate) 

  

- 3 - 

 
be adjusted in accordance with those provisions of the Company’s Amended and Restated Certificate of Incorporation, a copy of which is attached hereto as Exhibit B (the
“Certificate”), which apply to Diluting Issuances (the “Price Protection Provisions”) as if the Shares were outstanding on the date of such Diluting Issuance unless the adjustment that would have resulted from such Dilutive
Issuance has been duly waived by the requisite holders of the outstanding shares of Series E Preferred Stock in accordance with the terms of the Certificate, in which case such waiver shall also apply to the Shares. The Price Protection Provisions
in effect as of the Issue Date may not be amended, modified or waived, without the prior written consent of Holder unless such amendment, modification or waiver affects the rights associated with the Shares in the same manner as such amendment,
modification or waiver affects the rights associated with all other shares of the same series and class as the Shares granted to the Holder. Under no circumstances shall the aggregate Warrant Price payable by the Holder upon exercise of this Warrant
increase as a result of any adjustment arising from a Diluting Issuance. Notwithstanding the other provisions of this Section 2.4, by accepting this Warrant, the Holder hereby acknowledges that the holders of a requisite majority of the
outstanding the Series E Preferred Stock have consented to the conversion of all of the outstanding shares of Series E Preferred Stock into shares of the Company’s common stock in connection with the Company’s initial public offering and
that any conversion effectuated as a result of such consent shall be binding on any Shares issued to the Holder upon the exercise of this Warrant. In addition, by accepting this Warrant, the Holder hereby acknowledges that upon the consummation of
the Company’s initial public offering, the Certificate will be amended and restated to, among other things, delete the rights, limitations, privileges and designations of the Company’s existing preferred stock, including the Price
Protection Provisions, and that, from and after such amendment and restatement, (i) this Warrant shall be exercisable only for shares of the Company’s common stock and (ii) the provisions of this Section 2.4 will be of no further
force and effect. 
 2.5 No Impairment. The Company shall not, by amendment of its Amended and Restated Certificate of
Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or
performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this
Article 2 against impairment. 
 2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the
Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon
written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 
 2.7 Fractional Shares. No fractional Shares shall be issuable upon exercise of this Warrant and the Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional
share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest by paying Holder an amount computed by multiplying the fractional interest by the fair market value, as determined by the
Company’s Board of Directors, of a full Share. 
 ARTICLE 3 

REPRESENTATIONS AND COVENANTS OF THE COMPANY 
 3.1 Representations and Warranties. The Company hereby represents and warrants to, and agrees with, the Holder as follows: 
 3.1.1 The initial Warrant Price referenced on the first page of this Warrant is the lowest price at which the Shares have been issued prior to the date of this Warrant. 

  

- 4 - 

 3.1.2 All Shares which may be issued upon the exercise of the purchase right represented by
this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer
provided for herein or under applicable federal and state securities laws. 
 3.1.3 The Company’s capitalization table
delivered to Holder as of the Issue Date is true and complete as of the Issue Date. 
 3.2 Notice of Certain Events. If
the Company proposes at any time (a) to declare any dividend or distribution upon its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the
holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) to effect any reclassification or recapitalization of stock; or (d) to merge or consolidate with or into any other
corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (1) at least twenty (20) days prior
written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of stock will be entitled thereto) or for determining rights to vote, if any, in respect
of the matters referred to in (a) and (b) above; and (2) in the case of the matters referred to in (c) and (d) above at least twenty (20) days prior written notice of the date when the same will take place (and
specifying the date on which the holders of stock will be entitled to exchange their stock for securities or other property deliverable upon the occurrence of such event). Upon request, the Company shall provide Holder with such information
reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant Shares in the case of matters referred to (a), (b), (c) and (d) herein above. 

3.3 Information Rights. So long as the Holder holds this Warrant and/or any of the Shares, the Company shall deliver to the Holder
(a) promptly after mailing, copies of all communications, information and/or communiqués to the shareholders of the Company, (b) within one hundred eighty (180) days after the end of each fiscal year of the Company, the annual
audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s
quarterly, unaudited financial statements. In addition, and without limiting the generality of the foregoing, so long as the Holder holds this Warrant and/or any of the Shares, the Company shall afford to the Holder the same access to information
concerning the Company and its business and financial condition as would be afforded to a holder of the class of Shares under applicable state law and/or any agreement with any holder of the class of Shares. 

3.4 Registration Under the Act. The Company agrees that the Shares or, if the Shares are convertible into common stock of the
Company, such common stock, shall be deemed “Registrable Securities” or otherwise entitled to “piggy back” registration rights in accordance with the terms of the that certain Third Amended and Restated Investors’ Rights
Agreement between the Company and its investors dated as of December 19, 2012 (the “Agreement”), a copy of which is attached hereto as Exhibit C. The Company agrees that no amendments will be made to the Agreement which would
have an adverse impact on Holder’s registration rights hereunder this provision. Holder shall be deemed to be a party to the Agreement solely for the purpose of the above-mentioned registration rights. 

  

- 5 - 

 ARTICLE 4 
 MISCELLANEOUS 
 4.1 Term; Exercise Upon Expiration. This Warrant is
exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above; provided, however, that if the Company completes its initial public offering within the three-year period immediately prior
to the Expiration Date, the Expiration Date shall automatically be extended until the third anniversary of the effective date of the Company’s initial public offering. The Company shall give Holder written notice of Holder’s right to
exercise this Warrant not less than ninety (90) days before the Expiration Date. If the notice is not so given, the Expiration Date shall automatically be extended until ninety (90) days after the date the Company delivers such notice to
Holder. The Company agrees that Holder may terminate this Warrant, upon notice to the Company, at any time in its sole discretion. 
 4.2 Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following
form: 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 4.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the
Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. The Company shall not require Comerica Bank (“Bank”)
or a Bank Affiliate (as defined herein) to provide an opinion of counsel or investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated (“Comerica”), or any other affiliate of Bank
(“Bank Affiliate”). 
 4.4 Transfer Procedure. After receipt of the executed Warrant, Bank will transfer all of
this Warrant to Comerica Ventures Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”). Subject to the provisions of Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable
upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of this Warrant being transferred setting forth the name, address and taxpayer
identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that Holder may transfer all or part of this Warrant to its affiliates,
including, without limitation, Ventures, at any time without notice or the delivery of any other instrument to the Company, and such affiliate shall then be entitled to all the rights of Holder under this Warrant and any related agreements, and the
Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant is issued in the name of the affiliate that exercises this Warrant. The terms and conditions of this Warrant shall inure to the benefit of, and be binding
upon, the Company and the holders hereof and their respective permitted successors and assigns. 

  

- 6 - 

 4.5 Notices. All notices and other communications from the Company to the Holder, or
vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a nationally recognized overnight courier service, fee prepaid, or on the first business
day after transmission by facsimile, at such address or facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. Effective upon the receipt of executed
Warrant and initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

Comerica Ventures Incorporated 
 Attn: Warrant Administrator 
 1717 Main Street, 5th Floor, MC 6406 

Dallas, Texas 75201 
 FAX: XXX XXX XXXX 
 All notices to the Company shall be addressed as follows:

 REGADO BIOSCIENCES, INC. 
 120 Mountain View Blvd. 
 Basking Ridge, NJ 07920 

Attn: Chief Financial Officer 
 FAX: XXX XXX XXXX 
 4.6 Amendments; Waiver. This Warrant and any term
hereof may be amended, changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such amendment, change, waiver, discharge or termination is sought. 

4.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 
 4.8 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law.

 4.9 Confidentiality. The Company hereby agrees to keep the terms and conditions of this Warrant confidential.
Notwithstanding the foregoing confidentiality obligation, the Company may disclose information relating to this Warrant as required by law, rule, regulation, court order or other legal authority, provided that (i) the Company has given Holder
at least ten (10) days’ notice of such required disclosure, and (ii) the Company only discloses information that is required, in the opinion of counsel reasonably satisfactory to Holder, to be disclosed. 

4.10 Lock-Up Agreement. The Holder agrees that the Shares shall be subject to the 180 day lock-up period set forth in that certain
Lock-Up letter agreement “Regarding Regado Biosciences, Inc. Registration Statement on Form S-1 for Shares of Comon Stock” dated as of February 6, 2013 in the form provided to Holder as of the Issue Date provided that all
officers, directors and stockholders holding more than 1% of the Company on a fully diluted basis are also bound by such lock-up agreement. 
 [remainder of page intentionally left blank; signature page follows] 

  

- 7 - 

 
			
	REGADO BIOSCIENCES, INC.
		
	By:	 	 /s/ Chris Courts

		
	Name:	 	 Chris Courts

		
	Title:	 	 VP Finance

  

- 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]